176492-82-3

Upstream product

• 124-63-0 methanesulfonyl chloride 
• 176492-85-6 2,2'-(4-nitro-1,2-phenylene)diacetic acid 
• 7500-53-0 1,2-Phenylenediacetic acid 

Downstream Products

• 1016265-86-3 2-(2-azidoethyl)-4-nitrophenethyl methanesulfonate 
• 1016265-84-1 2-(2-azidoethyl)-5-nitrophenethyl methanesulfonate 
• 34583-83-0 7-nitro-2,3,4,5-tetrahydro-1H-benzo[d]azepiney 
• 118454-24-3 7-amino-1,2,4,5-tetrahydro-benzo[d]azepine-3-carboxylic acid tert-butyl ester 

Relevant academic research and scientific papers

HETEROARYL COMPOUNDS AND USES THEREOF

The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same. It has now been found that compounds of this invention, and pharmaceutically acceptable compositions thereof, are effective as inhibitors of one or more protein kinases. Such compounds have general formula I or a pharmaceutically acceptable salt thereof, wherein Ring A, Ring B, W, Ry, R3 and R4 are as defined herein.

USE OF ION CHANNEL MODULATORS IN THE PROPHYLAXIS AND TREATMENT OF INFLAMMATORY AND IMMUNOLOGICAL DISEASES

Use of compounds of general formula (1) and pharmacologically acceptable salts and prodrugs thereof:Formula (1) wherein A and B are CH2 or CH2CH2, R1 is hydrogen, alkyl, cycloalkyl, aryl, aralkyl or heteroaralkyl, R2, R3 and R4 are selected from hydrogen, alkyl, halogen, haloalkyl, alkoxy, alkoxycarbonyl, carboxyl, hydroxyl or cyano; X is R5CO, R5SO2, R5R7NCO, R5R7NSO2, R5SO2NR7CO or CO2R8, Y is R6CO, R6SO2, R6R7NCO, R6R7NSO2, R6SO2NR7CO or CO2R8, R5 and R6 are hydrogen, alkyl, aryl, aralkyl, heteroaryl or heteroaralkyl, R7 is hydrogen, alkyl, aryl or aralkyl, and R8 is alkyl, aryl, aralkyl, alkoxyalkyl, heteroaryl or heteroarylalkyl, provided that when X is R5CO or R5SO2, then Y is not R6CO, R6SO2 or R6R7NCO, in the manufacture of a medicament for the prophylaxis or treatment of inflammatory or immunological disease.